John Theurer Cancer Center Researchers Share 46 Cutting Edge Studies at 2017 ASH Meeting

Published: Saturday, Dec 09, 2017

Other novel therapies and new combinations in blood cancers
  • 410 - Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101), Oral Presentation, Sunday, December 10, 2017: 12:15 PM, Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)
  • 891 - Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles, Oral Presentation, Monday, December 11, 2017: 6:45 PM, Bldg B, Lvl 5, Murphy BR 1-2 (Georgia World Congress Center)


“Our research presented at this conference would not have been possible without the patients who participate in our clinical trials,” said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer, professor and vice president of cancer services, John Theurer Cancer Center. “We are thankful to our patients, our researchers, and our partnering institutions who help us bring novel therapies and improved regimens for cancer patients.”

For more information about the ASH conference or the research being presented, go to www.hematology.org/Annual-Meeting/.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x